by Market Overview:
Atezolizumab is a programmed cell death-ligand 1 (PD-L1) blocking antibody used for immunotherapy. It is used to treat various cancers including lung cancer, urothelial carcinoma, and breast cancer. Atezolizumab stimulates the immune system by blocking PD-L1, which leads to killing of cancer cells.
Market key trends:
One of the key trends in the atezolizumab market is its increasing use in combination therapies. Atezolizumab is increasingly being used in combination with bevacizumab, carboplatin, and paclitaxel for treating non-squamous non-small cell lung cancer. It is also being studied for use with targeted therapies like ramucirumab for gastric cancer and encorafenib and binimetinib for BRAF-mutant solid tumors. The combination therapy approach leads to improved efficacy by recruiting multiple pathways of the immune system against cancer cells.
One of the key trends in the Atezolizumab market is the rising adoption of immunotherapy for treatment of various types of cancers. Atezolizumab is a type of immunotherapy known as checkpoint inhibitor that helps boost the body’s natural defenses to fight cancer. It has demonstrated positive outcomes in clinical trials for lung, renal, bladder and other cancers. Its success as monotherapy or combination therapy has encouraged more oncologists to consider it as a treatment option.
The global Atezolizumab Market Share is estimated to be valued at US$ 2.68 Bn in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strengths: High efficacy and improved survival rates for various cancers. Better safety profile than chemotherapy.
Weaknesses: High cost of development and production. Potential side effects on immune system.
Opportunities: Potential expansion into new cancer indications. Combination therapies to enhance efficacy.
Threats: Patent expiration and launch of biosimilars. Development of competitor drugs.
The global Atezolizumab market is expected to witness high growth, exhibiting CAGR of 16.% over the forecast period, due to increasing incidence of cancer worldwide. According to GLOBOCAN 2020, global cancer burden rose to 19.3 million new cases and 10 million cancer deaths in 2020. This has accelerated research on novel therapeutics.
North America currently dominates the Atezolizumab market owing to supportive regulations, high healthcare spending and presence of key market players. However, Asia Pacific is projected to witness the highest growth during the forecast period driven by growing cancer prevalence, rising disposable incomes and improving access to advanced treatments in countries such as China and India.
Key players operating in the Atezolizumab market include Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie. Roche’s Tecentriq (atezolizumab) is currently the leading brand, approved for various cancer types including lung, kidney, bladder and others. Other players are focused on developing combination therapies to further enhance efficacy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
